Vaccine Delivery Articles & Analysis
31 news found
As reported by UCLA Health, a novel cancer vaccine could trigger robust immune responses in patients with pancreatic and colorectal cancer, driving a growing wave of research excitement around cancer vaccines. ...
The development of vaccines against superbugs is an important area of research because vaccines can help prevent infections from occurring in the first place and reduce the need for antibiotics. ...
Boston: Microneedle technology, driven by high demand in dermatologic procedures and its versatile applications in drug delivery, vaccine administration, and disease diagnostics, faces challenges in its complex manufacturing process. ...
Bio-ink products at Matexcel have been specifically designed for a variety of biomedical applications including embolization, wound healing, drug delivery, vaccines and so on. "Matexcel understands the unique needs of each bioprinting application," explained Johnson, one of the representative speakers from Matexcel. ...
ByMatexcel
By keeping up with the latest advancements in the field, its team of expert scientists possesses a deep knowledge of RNA biology, viral vectors, antigen design, and delivery systems. This expertise allows them to design and develop highly effective and safe mRNA vaccine candidates. ...
The featured vaccine products supplied by Alfa Chemistry are listed as below: Nucleic Acid Delivery ExcipientsNucleotide vaccines, including mRNA vaccines with their intracellular antigen synthesis, have been shown to be potent activators of a cytotoxic immune response. However, the intracellular delivery of mRNA ...
Lumen Bioscience, a clinical-stage biotechnology company developing biologic drugs for highly prevalent diseases, today announced the publication of data demonstrating a needle-free, spirulina-produced recombinant vaccine that protects against malaria. The research, conducted in collaboration with the University of Washington, was published in the peer-reviewed ...
The sublingual COVID-19 vaccine uses sublingual mucosal delivery technology to deliver the vaccine to the mucous membrane. ...
Mark Prausnitz, co-founder and Chief Scientific Advisor of Micron Biomedical (“Micron”), today presented Micron’s technology for the simple administration of vaccines and therapeutics at a White House panel discussion titled Innovation in Vaccine Delivery chaired by Dr. ...
Ziphius Vaccines (the “Company” or “Ziphius”), a biopharmaceutical company developing transformative self-amplifying RNA (saRNA) based medicinal products for vaccine and therapeutic applications, and University of Antwerp today announce that they have entered into a collaboration agreement to research and develop a dynamic lipid ...
Australian biotechnology company, Vaxxas Pty Ltd (Vaxxas), in collaboration with the University of Sydney Institute for Infectious Diseases, Faculty of Medicine and Health, has completed a study assessing the usability and acceptability of its novel High-Density Microarray Patch (HD-MAP) to administer vaccines. The HD-MAP is Vaxxas’ proprietary vaccine ...
ApiJect Holdings, Inc., the parent company of ApiJect Systems, Corp., a medical technology public-benefit corporation transforming the fill and finish and delivery of injectable vaccines and medicines, announced today that it had completed a $111 million private round of investment. ...
Abera is a biotechnology company with several proprietary vaccine platforms. The company has a vaccine candidate against pneumococcus that is being prepared for clinical phase evaluation and several pre-clinical vaccine candidates against other bacterial and viral infections. ...
Expands Pfizer’s access to lipid nanoparticle (LNP) formulation technology, offering a strong strategic fit with Pfizer’s mRNA strategy Pfizer gains option to license Acuitas’ LNP technology for up to 10 targets for vaccine or therapeutic development Pfizer Inc. (NYSE: PFE) and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) ...
Oravax’s oral vaccine targets three surface proteins, making it potentially more effective against current and future variants Oravax’s oral vaccine should offer critical advantages, including logistics, distribution and delivery in less vaccinated regions, including Africa Oramed Pharmaceuticals Inc. ...
In a new study, scientists report that they have successfully freeze-dried a liposome-based liquid vaccine formula that could be developed for potential use in COVID-19 vaccines. A vaccine that employs the freeze-dried liposomes is still a long way off. ...
Following months of collaborative development work, Aerogen® (Galway, Ireland) and CanSinoBIO (SSE: 688185, HKEX: 06185) (Tianjin, China) have announced a development and commercial supply partnership for the inhaled delivery of CanSinoBIO’s Recombinant Novel Coronavirus Vaccine Convidecia™ utilizing Aerogen’s proprietary vibrating mesh ...
ByAerogen
The award supports a collaboration between POP BIO and the Texas Biomedical Research Institute (Texas Biomed), with the goal of using POP BIO’s next-generation vaccine delivery platform to generate a novel vaccine that seeks to break the cold-chain requirements, and the resulting costs and challenges associated with the need to maintain the ...
Abera Bioscience AB (“Abera” or “the Company”) continues to improve its vaccine platform in collaboration with researchers at Vrije Universiteit Amsterdam. ...
Enesi Pharma Ltd (“Enesi”), an innovative biotechnology company developing next-generation vaccination products, targeting infectious diseases and emergent threat pathogens, enabled by its world leading ImplaVax® technologies, is delighted to announce the appointment of Elizabeth Eagling-Vose, MBA, as Senior Vice President, Operations. ...